IFNG and lung carcinoma: In addition, TP53 mutation has been confirmed as an indicator of anti-PD1 therapy in lung cancer (41) and can be associated with upregulated interferon-gamma levels and expression of immune checkpoints, as well as activation of effector T cells in lung adenocarcinoma (21).